the optimal dosing for intravenous OV delivery is unclear as the virus will be diluted in the peripheral circulation, making bioavailable titres at any individual tumour site unpredictable. In addition, viral particles could be prematurely cleared by circulating neutralizing factors (such as by antiviral antibodies or complement) that might further limit the effective dose of available virus at any given lesion. Thus, further studies on intravenous delivery are needed to better understand the pharmacokinetics of specific OVs upon entering the systemic circulation
IMU Price at posting:
13.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)